Company profile
4D MOLECULAR THERAPEUTICS, INC.
NASDAQ:FDMTBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| DUVALGAGENE OTIPARVOVEC | phase1_2 | — | 2 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04517149 | phase1_2 | active_not_recruiting | 2020-06-09 | 2026-06-01 | 4D Molecular Therapeutics | 4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP) |
| NCT05930561 | phase2 | active_not_recruiting | 2023-08-09 | 2029-02-28 | 4D Molecular Therapeutics | 4D-150 in Patients With Diabetic Macular Edema |
| NCT06864988 | phase3 | active_not_recruiting | 2025-03-03 | 2027-06-01 | 4D Molecular Therapeutics | 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration |
| NCT05197270 | phase1_2 | recruiting | 2021-12-09 | 2027-03-01 | 4D Molecular Therapeutics | 4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration |
| NCT05629559 | phase1_2 | recruiting | 2022-10-16 | 2026-06-01 | 4D Molecular Therapeutics | 4D-310 in Adults With Fabry Disease and Cardiac Involvement |
FDA applications (0)
No records yet.